A Study of PF-04217903 in Patients With Advanced Cancer
Status:
Terminated
Trial end date:
2011-06-01
Target enrollment:
Participant gender:
Summary
PF-04217903 may work in cancer by blocking the cell growth, migration and invasion of tumor
cells. PF-04217903 is a new member in a class of drugs called c-Met/hepatocyte growth factor
receptor tyrosine kinase inhibitors. This research study is the first time PF-04217903 will
be given to patients. PF-04217903 is taken by mouth daily.